HOME2024-09-10T10:15:12+01:00

Your Trusted Partner in Genotoxicity and Toxicology Services

Genotoxicity CRO Services

Icon of a laboratory flask, symbolizing Gentronix’s services in genetic toxicology screening.

Genetic Toxicology Screening

We offer a broad range of rapid turnaround screens, focussed on low test item usage, to detect and contextualise genotoxic liability early in development.

Clipboard icon denoting Gentronix's regulatory genotoxicity studies, highlighting organisation and documentation in testing.

Regulatory Genotoxicity Studies

We offer various GLP in vitro and in vivo genotoxicity studies that allow clients to demonstrate chemical safety and address their regulatory requirements.

Icon showing a shield with multiple layers of skin, representing skin toxicology services at Gentronix.

Skin Toxicology

Providing corrosion, irritation and skin sensitisation assays, we enable a comprehensive assessment of dermal toxicology potential.

Flow cytometer icon used to denote Gentronix's flow cytometry services, essential for detailed cellular analysis.

Flow Cytometry Services

Working with our clients, we utilise our flow cytometry experience and expertise to deliver a diverse range of endpoints.

ABOUT US

Gentronix is a specialist CRO focused on delivering predictive toxicology products & services to global chemical sectors. Working with companies from early screening through to regulatory safety assessment, we deliver innovative solutions for both genetic toxicology and skin sensitisation.

Mission & values

Our business origins are in delivering innovative screening products for toxicological hazards, challenging the established approach with scientific rigour. Building on our experiences of developing market-leading predictive toxicology assays, we have extended our expertise to regulatory tests for genetic toxicology and, recently, skin sensitisation. We make a commitment to our clients to perform toxicology studies of the highest scientific quality, not merely to produce data but to deliver the most appropriate data endpoints using the right assay tools, guided by scientific engagement and experience. Furthermore, we are committed to helping our clients understand and interpret their results, supporting the navigation of regulatory landscapes and managing adverse toxicology findings.

FInd out more

Predictive Screening & Safety

Gentronix provides predictive toxicology services that enable our clients to gain an early-stage view of toxicological hazards, facilitating the identification of challenges and allowing management of these whilst there is still time. In addition, we provide services and expertise to regulatory assay services that are required for chemical submission and safety assessment. These capabilities allow you to work with a company that gives you the benefit of both our screening expertise and scientific commitment to chemical safety.

FInd out more

GET IN TOUCH

Do you need toxicology support for your project? Please get in touch by either completing the form below or contacting one of our team directly.

OUR BLOG

MEET THE TEAM

Matt Tate, Managing Director of Gentronix
Now leading the business, Matt develops our overall strategy, delivering our plan to build an expert predictive toxicology CRO.
Dr Matt Tate, Managing Director
Nick Billinton, Operations Director at Gentronix
As Operations Director, Nick continues to ensure our commitment to expert delivery of high quality science is maintained.
Dr Nick Billinton, Operations Director

Your Trusted Partner in Genotoxicity and Toxicology Services

Scantox Group acquires Gentronix, a world leader in genetic toxicology

September 6th, 2024

2024-09-06, Jeanet Løgsted, Scantox_Matt Tate, GentronixToday Scantox, together with its majority owner Impilo, finalized the acquisition of Gentronix Ltd, a UK based GLP compliant genetic toxicology Contract Research Organization (“CRO”). 

Gentronix, now integrated into Scantox Group, is well recognized for its high-quality genetic toxicology services and strong scientific engagement, with an undisputed track record of serving a loyal and broad global customer base. With the acquisition of Gentronix, Scantox’s service platform expands significantly to meet client demands as a market leading CRO to support pre-IND enabling studies.

For 25 years, Gentronix has provided genetic toxicology solutions to the global pharma, biotech and agrichem industries; enabling clients to optimize their development programs by enabling early identification of genotoxic compounds and supporting late-stage development phases with GLP studies. Gentronix offers a comprehensive portfolio of screening and regulatory genotoxicity assays and services, not least the OECD 488 Big Blue® Transgenic Rodent Mutation assay, as one of only three global providers. Further, Gentronix has expertise and services within ocular and skin toxicology endpoints.

Founded in 1999 by Prof. Richard Walmsely, Gentronix is located within the North West UK at the Alderley Park and employs close to 70 employees after a significant scale-up over the past 5 years.

“I am thrilled that Scantox Group has been able to partner up with Gentronix. Genetic toxicology is a missing link in our portfolio and frequently requested by our clients to become a one-stop-shop premier CRO partner. Gentronix´s service line, client base, high quality standards and not least people culture fits perfectly with our DNA. Our business plan is to continuously expand our service portfolio across all sites and add scientific excellence to the Group,” says Jeanet Løgsted, CEO of Scantox Group. 

Matt Tate, CEO of Gentronix, adds: “Becoming a part of Scantox Group is a fantastic next step for Gentronix, opening up unique possibilities for us to offer an even greater service portfolio to our clients. As an organization we look forward to collaborating with our new colleagues and continuing to support the delivery of world-leading contract research services to our customers. There is a strong strategic rationale in teaming up with Scantox and we have identified multiple commercial synergies”.

Gentronix Ltd will continue to operate under the current company name, expanding its service offering within specialist regulatory toxicology. With this acquisition the Scantox Group will employ more than 400 people across seven European sites offering first in class lead optimization, regulatory toxicology and CMC (Chemical, Manufacturing, Controls), formulation and analytical services.

Nicholas Hooge, Partner at Impilo, concludes, “We are thrilled to welcome Gentronix into the Scantox group and see significant growth opportunities for the combined business going forward. 2024 is in many ways a transformational year for Scantox and this acquisition represents another important milestone in reaching Scantox’ strategic ambitions.”

Go to Top